Impact of systemic therapies in metastatic ...
Type de document :
Compte-rendu et recension critique d'ouvrage
PMID :
Titre :
Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort
Auteur(s) :
Rousset, Perrine [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Dalle, Stéphane [Auteur]
Centre Léon Bérard [Lyon]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Mortier, Laurent [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Dereure, Olivier [Auteur]
Pathogenesis and Control of Chronic and Emerging Infections [PCCEI]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Dalac, Sophie [Auteur]
Service de Dermatologie (CHU de Dijon)
Dutriaux, Caroline [Auteur]
CHU Bordeaux
Leccia, Marie-Thérèse [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Legoupil, Delphine [Auteur]
Centre Hospitalier Régional Universitaire de Brest [CHRU Brest]
Brunet-Possenti, Florence [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
de Quatrebarbes, Julie [Auteur]
Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
Grob, Jean-Jacques [Auteur]
Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM]
Saiag, Philippe [Auteur]
Hôpital Ambroise Paré [AP-HP]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie [BECCOH]
Maubec, Eve [Auteur]
Hôpital Avicenne [AP-HP]
Stoebner, Pierre-Emmanuel [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Institut de Recherche en Cancérologie de Montpellier [IRCM - U1194 Inserm - UM]
Granel-Brocard, Florence [Auteur]
Service de Dermatologie et Allergologie [CHRU Nancy]
Arnault, Jean-Philippe [Auteur]
CHU Amiens-Picardie
Allayous, Clara [Auteur]
Service de Dermatologie [AP-HP Hôpital Saint-Louis]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Oriano, Bastien [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Hôpital Hôtel-Dieu [Paris]
Lebbé, Celeste [Auteur]
Assistance publique - Hôpitaux de Paris (AP-HP) [AP-HP]
Montaudié, Henri [Auteur]
Service de Dermatologie [Nice]
Centre méditerranéen de médecine moléculaire [C3M]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Dalle, Stéphane [Auteur]
Centre Léon Bérard [Lyon]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Mortier, Laurent [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Dereure, Olivier [Auteur]
Pathogenesis and Control of Chronic and Emerging Infections [PCCEI]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Dalac, Sophie [Auteur]
Service de Dermatologie (CHU de Dijon)
Dutriaux, Caroline [Auteur]
CHU Bordeaux
Leccia, Marie-Thérèse [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Legoupil, Delphine [Auteur]
Centre Hospitalier Régional Universitaire de Brest [CHRU Brest]
Brunet-Possenti, Florence [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
de Quatrebarbes, Julie [Auteur]
Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
Grob, Jean-Jacques [Auteur]
Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM]
Saiag, Philippe [Auteur]
Hôpital Ambroise Paré [AP-HP]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie [BECCOH]
Maubec, Eve [Auteur]
Hôpital Avicenne [AP-HP]
Stoebner, Pierre-Emmanuel [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Institut de Recherche en Cancérologie de Montpellier [IRCM - U1194 Inserm - UM]
Granel-Brocard, Florence [Auteur]
Service de Dermatologie et Allergologie [CHRU Nancy]
Arnault, Jean-Philippe [Auteur]
CHU Amiens-Picardie
Allayous, Clara [Auteur]
Service de Dermatologie [AP-HP Hôpital Saint-Louis]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Oriano, Bastien [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Hôpital Hôtel-Dieu [Paris]
Lebbé, Celeste [Auteur]
Assistance publique - Hôpitaux de Paris (AP-HP) [AP-HP]
Montaudié, Henri [Auteur]
Service de Dermatologie [Nice]
Centre méditerranéen de médecine moléculaire [C3M]
Titre de la revue :
Journal of the American Academy of Dermatology
Pagination :
808-815
Éditeur :
Elsevier
Date de publication :
2023-04
ISSN :
0190-9622
Mot(s)-clé(s) en anglais :
Advanced melanoma
Adverse events
Chemotherapy
Immunotherapy
Melanoma of known primary
Melanoma of unknown primary
Survival
Systemic therapy
Targeted therapy
Adverse events
Chemotherapy
Immunotherapy
Melanoma of known primary
Melanoma of unknown primary
Survival
Systemic therapy
Targeted therapy
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie
Résumé en anglais : [en]
Background: Clinical outcomes of advanced melanoma of unknown primary (MUP) in the era of novel therapies have been scarcely studied.Objective: To investigate the efficacy and safety of systemic treatments in patients with ...
Lire la suite >Background: Clinical outcomes of advanced melanoma of unknown primary (MUP) in the era of novel therapies have been scarcely studied.Objective: To investigate the efficacy and safety of systemic treatments in patients with advanced MUP compared to patients with stage-matched melanoma of known cutaneous primary (cMKP).Methods: Based on the nationwide MelBase prospective database, this study included advanced melanoma patients treated from March 2013 to June 2021 with first-line immunotherapies, targeted therapies, or chemotherapy. Co-primary outcomes were progression-free survival and overall survival. Secondary outcome was treatment-related toxicities. Multivariate and propensity score analyses were performed.Results: Of 1882 patients, 265 (14.1%) had advanced MUP. Patients with advanced MUP displayed more often unfavorable initial prognostic factors than those with cMKP. Progression-free and overall survival did not differ significantly between the groups (P = .73 and P = .93, respectively), as well as treatment-related toxicity rate and severity, regardless of treatment type.Limitations: No record of standard diagnostic criteria of MUP used in the participating centers.Conclusions: Although patients with MUP had less favorable baseline prognostic factors, they benefited from the novel therapies as much as those with cMKP. They should be managed according to similar strategies.Lire moins >
Lire la suite >Background: Clinical outcomes of advanced melanoma of unknown primary (MUP) in the era of novel therapies have been scarcely studied.Objective: To investigate the efficacy and safety of systemic treatments in patients with advanced MUP compared to patients with stage-matched melanoma of known cutaneous primary (cMKP).Methods: Based on the nationwide MelBase prospective database, this study included advanced melanoma patients treated from March 2013 to June 2021 with first-line immunotherapies, targeted therapies, or chemotherapy. Co-primary outcomes were progression-free survival and overall survival. Secondary outcome was treatment-related toxicities. Multivariate and propensity score analyses were performed.Results: Of 1882 patients, 265 (14.1%) had advanced MUP. Patients with advanced MUP displayed more often unfavorable initial prognostic factors than those with cMKP. Progression-free and overall survival did not differ significantly between the groups (P = .73 and P = .93, respectively), as well as treatment-related toxicity rate and severity, regardless of treatment type.Limitations: No record of standard diagnostic criteria of MUP used in the participating centers.Conclusions: Although patients with MUP had less favorable baseline prognostic factors, they benefited from the novel therapies as much as those with cMKP. They should be managed according to similar strategies.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :